Prevalence of dyslipidemia in patients with systemic lupus erythematosus in Hospital Clínico Regional of Concepción

INTRODUCTION: Systemic lupus erythematosus is considered a cardiovascular risk factor. Dyslipidemia is commonly found in these patients. Corticosteroid therapy promotes lipid abnormalities. HYPOTHESES: Systemic lupus erythematosus patients with hypercholesterolemia, hypertriglyceridemia, or both, in greater proportion than the general population. OBJECTIVE: To determine the prevalence of dyslipidemia in patients diagnosed with systemic lupus erythematosus and monitored at the clinic of rheumatology, Hospital Clínico Regional Concepción. MATERIAL AND METHOD: A retrospective cross sectional in patients diagnosed with systemic lupus erythematosus and have controlled the last year in the Hospital Clínico Regional Concepción. The variables studied were: sex, age, hypercholesterolemia, hypertriglyceridemia, dose/duration of use of corticosteroids and hydroxichloroquine. RESULTS: Of all patients studied (n=154), 88.9% (n=137) women, mean age 45.6 +/- 5 years, 40.9% (n=43) presents hypertriglyceridemia, 55.2% (n=58) presented hypercholesterolemia presented and 65.9% (n=100) presented both alterations. Patients with minor changes 10 years: 50% (n=29) presents hypercholesterolemia; 34.5% (n=20) had hypertriglyceridemia. With 11-20 years of evolution: 56.25% (n=18) presents hypercholesterolemia; 45.75% (n=14) has hypertriglyceridemia. With over 20 years of evolution: 73.3% (n=11) has hypercholesterolemia; 60% (n=9) showed hypertriglyceridemia. Steroids users 89% (n=138) and 92.4% (n=142) using hixychloroquine. DISCUSSION: The main alteration is hypercholesterolemia. Patients with more years of evolution have a greater number of dyslipidemia than others patients. Most are steroid users. We conclude that the prevalence of dyslipidemia is more common in systemic lupus erythematosus patients than the general population. The more years of evolution, is a greater percentage of patients with dyslipidemia.